Please assess the completion status of the following clinical trial:

Trial Title: Direct and Indirect Protection by Influenza Vaccine Given to Children in India

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion in either vaccine group (TIV or IPV) will require ages 6 months through 10 years of age.~* All individuals in enrolled households will be eligible for enrollment into surveillance arm.~Exclusion Criteria:~* Exclusion criteria from the vaccine groups includes known allergy to eggs, or hypersensitivity to other components of a vaccine (streptomycin, neomycin, and polymyxin B)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Inactivated Polio Vaccine (IPV) (Type: ACTIVE_COMPARATOR): Inactivated trivalent poliovirus vaccine (IPV) age Dose # doses/year 1 # doses year 2 and 3 6 mo -8y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
- Inactivated Trivalent Influenza Vaccine (Type: EXPERIMENTAL): Inactivated split virion trivalent influenza vaccine (TIV) age Dose # doses year 1 # doses year 2 and 3 6-35 mo 0.25 ml 2 1 3-8 y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
- Surveillance arm (Type: NO_INTERVENTION): Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.

Based on this trial design, predict the completion outcome and termination type (if applicable).